| Pack Size/Qty | Price | Unit Price | |
| 90 Tablet/s | $95.00 | $1.06 | |
| 60 Tablet/s | $69.50 | $1.16 | |
| 30 Tablet/s | $34.80 | $1.16 |
Generic Name : Sitagliptin + Metformin Hcl.
Brand Name : Janumet
Manufacturer Name : Merck
Product Code : CRX 290
Delivery Days : 10 to 15 working days
Strength : 1000 mg
Packaging : Tablet/s (Blister Packing)
Prescribed For : Type 2 Diabetes, Control Blood Sugar Levels
Janumet 50mg/1000mg is a medication that combines two active ingredients, sitagliptin and metformin, to provide an effective treatment for individuals with type 2 diabetes. This medication belongs to a class of drugs known as antidiabetic agents, and its unique combination addresses different aspects of glucose regulation to help manage blood sugar levels in patients.
Let's delve into a comprehensive description of Janumet 50mg/1000mg, exploring its composition, mechanism of action, therapeutic effects, dosage, potential side effects, and other relevant aspects.
Janumet 50mg/1000mg is a fixed-dose combination tablet containing two key ingredients: sitagliptin and metformin. Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor, while metformin is a biguanide. Both ingredients play distinct roles in managing blood sugar levels, offering a complementary approach to diabetes treatment.
Sitagliptin works by inhibiting DPP-4, an enzyme that breaks down incretin hormones. Incretins stimulate the release of insulin and reduce the production of glucose by the liver. By inhibiting DPP-4, sitagliptin prolongs the action of incretins, resulting in increased insulin release and decreased glucagon levels. This helps control blood sugar levels after meals.
Metformin, on the other hand, primarily acts by reducing the production of glucose by the liver and improving the body's response to insulin. It also enhances the uptake of glucose by the muscles, thereby increasing insulin sensitivity. Additionally, metformin has been shown to have beneficial effects on weight and lipid profiles.
The combination of sitagliptin and metformin addresses multiple aspects of glucose homeostasis, making Janumet 50mg/1000mg a potent and comprehensive treatment option for type 2 diabetes.
The primary therapeutic goal of Janumet 50mg/1000mg is to help individuals with type 2 diabetes maintain optimal blood sugar levels. By combining the mechanisms of action of sitagliptin and metformin, this medication provides a balanced and effective approach to glucose regulation throughout the day, both in fasting and postprandial states.
The DPP-4 inhibition by sitagliptin helps control blood sugar spikes after meals, while metformin addresses insulin resistance and reduces the overproduction of glucose by the liver. This dual action is particularly valuable in managing the complexities of type 2 diabetes, where both impaired insulin secretion and increased insulin resistance contribute to elevated blood sugar levels.
Janumet 50mg/1000mg is available in tablet form for oral administration. The dosage may vary depending on individual patient factors, including the severity of diabetes and other medical conditions. Typically, the recommended starting dose is one tablet twice daily with meals. The healthcare provider may adjust the dosage based on the patient's response and tolerability.
It is crucial for patients to adhere to the prescribed dosage and administration schedule to optimize the therapeutic benefits of Janumet 50mg/1000mg. Regular monitoring of blood sugar levels, as well as periodic medical check-ups, is essential to assess the treatment's effectiveness and make any necessary adjustments.
Like any medication, Janumet 50mg/1000mg may cause side effects in some individuals. Common side effects include gastrointestinal symptoms such as nausea, vomiting, and diarrhea, which are often mild and transient. These side effects can be minimized by taking the medication with meals.
Serious but rare side effects may include lactic acidosis, a potentially life-threatening condition associated with metformin use. Patients should be aware of symptoms such as rapid breathing, muscle pain, and drowsiness, and seek immediate medical attention if these occur.
It is essential for individuals taking Janumet 50mg/1000mg to communicate any unusual or persistent side effects to their healthcare provider promptly.
Before initiating treatment with Janumet 50mg/1000mg, healthcare providers should assess patients for contraindications and potential risks. This medication is contraindicated in individuals with a history of hypersensitivity to sitagliptin, metformin, or any of the components in the formulation. It should not be used in patients with severe renal impairment, acute or chronic metabolic acidosis, or a history of pancreatitis.
Special precautions are necessary for individuals with certain medical conditions, such as impaired renal function or heart failure. Regular monitoring of renal function and other relevant parameters is essential to ensure the safe and effective use of Janumet 50mg/1000mg.
In summary, Janumet 50mg/1000mg is a combination medication designed to address the complexities of type 2 diabetes by incorporating the synergistic actions of sitagliptin and metformin. Its dual mechanism of action targets both insulin secretion and insulin resistance, offering a comprehensive approach to blood sugar control.
While Janumet 50mg/1000mg has demonstrated efficacy in managing type 2 diabetes, it is crucial for healthcare providers to individualize treatment plans based on patient characteristics and closely monitor for potential side effects. As with any medication, patients should adhere to prescribed dosages, attend regular medical check-ups, and communicate any concerns or side effects to their healthcare team promptly.
